<DOC>
	<DOCNO>NCT00543101</DOCNO>
	<brief_summary>This study evaluate patient achieve virologic suppression ( &lt; 400 copies/mL ) dual protease inhibitor ( PI ) combination , determine whether patient substitute PIs single boost PI darunavir give 600/100 ritonavir ( RTV ) twice daily ( BID ) maintain comparable virologic suppression ( % &lt; 50 c/mL ) 24 week .</brief_summary>
	<brief_title>Efficacy Study Substitution Darunavir/Ritonavir ( DRV/r ) Dual-boosted Protease Inhibitors</brief_title>
	<detailed_description>The purpose study determine patient achieve virologic suppression ( &lt; 400 copies/mL ) dual PI combination , substitute PIs single boost PI darunavir give 600/100 rtv bid maintain comparable virologic suppression ( % &lt; 50 c/mL ) 24 week . Randomized , non-blinded , multicenter , 48 week , control trial ass non-inferiority substitute DRV/r dual boost PI combination patient stable virologic suppression regimen contain dual boost PI combination plus least one additional FDA-licensed antiretroviral agent another class . Participants randomize ( 1:1 ) one include treatment arm .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Age 18 year old Treatment stable antiretroviral regimen contain two protease inhibitor , one additional FDAlicensed agent another class ( except NNRTIs ) boost dosage ritonavir ( 100 BID QD ) least 12 week prior screen No plan make change HIV treatment regimen ( require study ) next 48 week . HIV1 RNA &lt; 400 copies/ml base recent value do part routine care least 12 week prior screen ; &lt; 400 screen Any CD4 count allow Written inform consent participate Current regimen include NNRTI CDC Class C Illness diagnose within 30 day screen Lab abnormality define standardized grade scheme base DAIDS table Any grade 3 4 toxicity follow exception : Preexisting diabetes glucose elevation ≥ grade 3 triglyceride total cholesterol elevation ≥ grade 3 Clinical laboratory evidence clinically significant liver impairment/dysfunction , disease cirrhosis Note : Individuals coinfected chronic hepatitis B C allow enter trial condition clinically stable . Individuals diagnose acute viral hepatitis screening allow enroll acute phase . Active substance abuse significant psychiatric illness opinion investigator might interfere study compliance . Use investigational agent 30 day prior screen Life expectancy &lt; 6 month opinion investigator Prior use darunavir know allergy component darunavir Breast feed Female subject childbearing potential use effective nonhormonal birth control method willing continue practice birth control method screen last trial related activity . Note : Hormonal base contraception may reliable take darunavir , therefore eligible study , woman childbearing potential may vaginal intercourse either : 1 . Use double barrier method prevent pregnancy ( i.e. , use condom either diaphragm cervical cap ) Or 2 . Use hormonal base contraceptive combination barrier contraceptive ( i.e. , male condom , diaphragm , cervical cap female condom ) Or 3 . Use intra uterine device ( IUD ) combination barrier contraceptive ( i.e. , male condom , diaphragm , cervical cap female condom ) Or 4 . Be nonheterosexually active , practice sexual abstinence vasectomize partner ( confirm sterile ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>HIV/AIDS</keyword>
	<keyword>darunavir</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Dual boost</keyword>
	<keyword>Treatment experience</keyword>
</DOC>